Additional Information
Market: NYSE, LSE, OTC
Sector: Pharmaceuticals & Biotech
Latest Price: 32.11  (1.01% Ascending)
52-week High: 75.38
52-week Low: 30.28
Market Cap: 81,174.10M
1 year chart
1 day chart

AstraZeneca is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation.

AstraZeneca boss sees progress despite profits slide

1st Aug 2013, 4:14 am by Philip Whiterow
Losing exclusivity on several key brands including Atacand, Nexium and Seroquel IR accounted for US$500mln in lost revenues. Losing exclusivity on several key brands including Atacand, Nexium and Seroquel IR accounted for US$500mln in lost revenues.

AstraZeneca (NYSE:AZN) (LON:AZN) is making "real progress" its boss said, despite generic drugs taking a chunk out of second quarter revenue and profits tumbling.

Chief executive Pascal Soriot said the late-stage drug pipeline is growing and added that the impact on revenue from the loss of exclusivity for key brands had been anticipated.

Losing protection on Atacand, Nexium and Seroquel IR accounted for US$500mln in lost revenues in the quarter to June with European sales hit especially hard and dropping by 13%. Cholesterol lowering treatment Crestor is also facing increased competition.

The five areas identified as growth markets by Astra, comprising emerging Markets, Japan, Brilinta and diabetes and respiratory products, helped to offset some of this and boosted revenues by US$400mln.

Revenues overall fell by 6% to US$6.23bn while pre-tax profits tumbled 38% to $1.09bn. Profits were 10% lower in the second quarter in the core businesses.

Over the first half, sales were down by 10% and profits 37% lower.

Soriot said: “Despite the fostamatinib [rheumatoid arthritis] disappointment, the late-stage pipeline in our core therapy areas is growing, and has been further strengthened with the acquisitions of Omthera Pharmaceuticals and Pearl Therapeutics and the recently announced collaboration with FibroGen.“

Astra left its forecasts for a mid-to-high single digit decline in revenues this year unchanged, but cautioned costs will now go up in the low-to-mid single digit range, a higher estimate than previously.

Shares fell 19 pence to 3,316 pence in London morning trade.

No investment advice

Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here